New research shows that a rare group of pancreatic cancer patients responded remarkably well to immunotherapy, a treatment typically considered ineffective for this cancer type.
When Robert Mayer was only a few years out of residency, in the 1970s, he signed on as an investigator of the NCI-supported Gastrointestinal Tumor Study Group, which conducted research into colorectal, gastric, and pancreatic cancers.
